1. Home
  2. SVAQ vs AGEN Comparison

SVAQ vs AGEN Comparison

Compare SVAQ & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silicon Valley Acquisition Corp. Class A Ordinary Shares

SVAQ

Silicon Valley Acquisition Corp. Class A Ordinary Shares

N/A

Current Price

$10.19

Market Cap

298.5M

Sector

Finance

ML Signal

N/A

Logo Agenus Inc.

AGEN

Agenus Inc.

SELL

Current Price

$6.29

Market Cap

335.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SVAQ
AGEN
Founded
2025
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
298.5M
335.6M
IPO Year
2025
1999

Fundamental Metrics

Financial Performance
Metric
SVAQ
AGEN
Price
$10.19
$6.29
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $27.00
AVG Volume (30 Days)
15.2K
★ 651.5K
Earning Date
01-01-0001
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 100.00
EPS
N/A
★ 0.60
Revenue
N/A
★ $42,877,086.00
Revenue This Year
N/A
$14.41
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$11.23
Revenue Growth
N/A
★ 89.95
52 Week Low
$9.86
$2.71
52 Week High
$10.20
$10.19

Technical Indicators

Market Signals
Indicator
SVAQ
AGEN
Relative Strength Index (RSI) 64.27 41.79
Support Level $10.14 $6.16
Resistance Level $10.20 $8.64
Average True Range (ATR) 0.01 0.47
MACD -0.00 0.02
Stochastic Oscillator 100.00 13.64

Price Performance

Historical Comparison
SVAQ
AGEN

About SVAQ Silicon Valley Acquisition Corp. Class A Ordinary Shares

Silicon Valley Acquisition Corp is a blank check company.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: